the reason i weighed into slt and pbi options is the fact they are so long dated, the technology looks so good and the commercialisation so close. i wouldn't touch the options if they had anything less than 2 years to go ... i felt that with the prospects of these two companies that the leverage to be gained for a patient investor was too good to miss. of course i'm often wrong, so i'll be selling a few in the near future and holding onto the rest for the future gains that may result.
as for select revenues .... i posted this the other day ... a shaw report was released about 12-15 month ago when slt was at .66. they were claiming that in the second year of the hep e deal, the first year of the hep a deal and the initial stages of the hep c deal that select would boast revenues totalling $US6.8million. So close to $10m australian a year. The break down was $800,000us hep e, $us4million hep a and $us2m hep c.
if it comes to pass, the maths is compelling ...
SLT Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
